Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px
Organisation › Details

Oxford BioTherapeutics Ltd. (OBT)

Oxford BioTherapeutics is a clinical stage oncology company based in Oxford, UK and San Jose, USA; with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfill major unmet patient needs in cancer therapeutics. These include bispecific, Chimeric Antigen Receptor T Cell (CAR-T), ADC and Antibody Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics. OBT's first clinical program, OBT076, initiated expansion in a U.S. Clinical Trial in 2021 in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed. Infiltration of tumors by immunosuppressive cells correlates with adverse outcomes (lower profession free and overall survival), suggesting that this process contributes to the progression of several cancers. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. OBT's IO discovery process provides unique insights into the cancer - immune cell synapse and has identified several novel IO monoclonal and bispecific antibody candidates for cancer therapies. OBT’s pipeline and development capabilities have been validated through multiple strategic partnerships including with Boehringer Ingelheim and our cell therapy research collaboration with Kite Pharma as well as other world leaders in antibody development (such as Amgen, Immunogen, WuXi, Medarex (BMS), Alere (Abbott), BioWa, and Nerviano). OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies. *

 

Period Start 2008-12-01 renamed
  Predecessor Oxford Genome Sciences (UK) Ltd. (OGeS)
Products Industry antibody-drug conjugate (ADC)
  Industry 2 Oxford Genome Anatomy Project (OGAP) database
Persons Person Rohlff, Christian (Oxford BioTherapeutics 201506 CEO before Oxford Genome Sciences CEO)
  Person 2 Wilson, Keith (Oxford BioTherapeutics 201506 CSO)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 94a Milton Park
  City OX14 4RY Abingdon, Oxfordshire
  Tel +44-1235-861770
    Address record changed: 2022-04-14
     
Basic data Employees n. a.
     
    * Document for �About Section�: Oxford BioTherapeutics Ltd.. (4/13/22). "Press Release: Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target". Oxford & San Jose, CA.
     
   
Record changed: 2022-04-14

Advertisement

Picture [iito] Männer Ballett 650x100px

More documents for Oxford BioTherapeutics Ltd. (OBT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top